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Abstract 14 
Primary immunodeficiencies are inherited disorders of the immune system, often caused by 15 
mutation of genes required for lymphocyte development and activation. Recently, several studies 16 
have identified gain-of-function mutations in the PI3K genes PIK3CD  ?Ɖ ? ? ?ɷ ?ĂŶĚPIK3R1  ?Ɖ ? ?ɲ ?ƚŚĂƚ17 
cause a combined immunodeficiency syndrome, referred to as Activated PI3K Delta Syndrome 18 
(APDS) or p110G-activating mutation causing senescent T cells, lymphadenopathy, and 19 
immunodeficiency (PASLI). Paradoxically, both loss- and gain-of-function mutations affecting these 20 
genes lead to immunosuppression, albeit via different mechanisms. Here we review the roles of 21 
W/ ?<ɷŝŶĂĚĂƉƚŝǀĞŝŵŵƵŶŝƚǇ ?describe the clinical manifestations and mechanisms of disease in APDS 22 
ĂŶĚŚŝŐŚůŝŐŚƚŶĞǁŝŶƐŝŐŚƚƐ ŝŶƚŽW/ ?<ɷŐůĞĂŶĞĚĨƌŽŵƚŚĞƐĞƉĂƚŝĞŶƚƐ ?ĂƐǁĞůůĂƐ ŝŵƉůŝĐĂƚŝŽŶƐŽĨƚŚĞƐĞ23 
findings for clinical therapy. 24 
   25 
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Introduction 26 
APDS is among a growing number of newly defined primary immunodeficiency (PID) [G] syndromes  27 
in which the causal mutations have been identified by next generation sequencing. The clinical 28 
manifestations of APDS are diverse and heterogeneous (Box 1), but the majority of patients present 29 
with recurrent respiratory infections, often associated with airway scarring (bronchiectasis) and ear 30 
and sinus damage suggestive of antibody (B cell) deficiency. Severe, recurrent or persistent 31 
infections with herpes family viruses indicating defective T cell function are also common in this 32 
condition, and may cause early death in some affected individuals. Many patients develop benign 33 
lymphadenopathy, often associated with hepatosplenomegaly, and there is a substantially increased 34 
risk of B cell lymphoma (Box 1). Increased susceptibility to viral infection and poor recall responses 35 
of memory T cells differentiate APDS from isolated hypogammaglobulinemia
1-4
, hence APDS should 36 
be considered a combined immunodeficiency
5
.  More than 100 patients have been reported so far 37 
with APDS, but the precise incidence is not yet known
6, 7
. 38 
APDS is caused by heterozygous gain-of-function (GOF) mutations in PIK3CD or PIK3R1 that induce 39 
hyperactivation of the protein products p1 ? ?ɷor Ɖ ? ?ɲ, respectively1-4. dŚĞƉ ? ?ɲƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚ40 
ĂŶĚƉ ? ? ?ɷĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚtogether ĨŽƌŵƚŚĞŚĞƚĞƌŽĚŝŵĞƌŝĐůŝƉŝĚŬŝŶĂƐĞW/ ?<ɷ ?ǁŚŝĐŚŝƐĞŶŐĂŐĞĚďǇ41 
multiple receptors in the immune system, including the BCR, TCR, and cytokine and costimulatory 42 
receptors. Homozygous loss-of-function (LOF) mutations in these same subunits cause a distinct and 43 
much rarer form of immunodeficiency in humans, which can be re-capitulated in mice
8-10
, and this 44 
apparent dichotomy, together with the clinical features of the affected patient groups, has informed 45 
our understanding of the role of W/ ?<ɷ in immune cell development and function. 46 
Overview of class I PI3Ks  47 
The class IA W/ ?<Ɛ ĐŽŵƉƌŝƐĞ Ɖ ? ? ?ɲ ? Ɖ ? ? ?ɴ Žƌ Ɖ ? ? ?ɷ ĐĂƚĂůǇƚŝĐ ƐƵďƵŶŝƚƐ, which form heterodimeric 48 
complexes with a p85 regulatory subunit; the sole class IB PI3K, Ɖ ? ? ?ɶ, interacts with a p101 or p84 49 
regulatory subunit (Table 1). P ? ? ?ɲĂŶĚƉ ? ? ?ɴĂƌĞďƌŽĂĚůǇĞǆƉƌĞƐƐĞĚ, ǁŚĞƌĞĂƐƉ ? ? ?ɶĂŶĚƉ ? ? ?ɷare 50 
found predominantly in leukocytes. Although there is significant potential for redundancy among the 51 
catalytic subunits, unique roles for each individual p110 isoform have been described, reflecting 52 
their different expression patterns as well as how they are engaged by their respective receptors
8, 11
. 53 
&Žƌ ĞǆĂŵƉůĞ ? Ɖ ? ? ?ɲis activated by insulin-like receptors and regulates growth, metabolism and 54 
angiogenesis
11 ?W ? ? ?ɴĐĂŶĂůƐŽĐŽŶƚƌŝďƵƚĞ ƚŽŵĞƚĂďŽůŝĐ ƐŝŐŶĂůůŝŶŐĂŶĚŚĂƐďĞĞŶƐŚŽǁŶ ƚŽ ƌĞŐƵůĂƚĞ55 
responses of mouse neutrophils to antigen-antibody complexes
12, 13 ? W ? ? ?ɶ ŝƐ ŚŝŐŚůǇ ĞǆƉƌĞƐƐĞĚ ŝŶ56 
myeloid cells and contributes to chemotactic responses as well as reactive oxygen species 57 
production in neutrophils
14 ? dŽŐĞƚŚĞƌ ǁŝƚŚ Ɖ ? ? ?ɷ ? Ɖ ? ? ?ɶ ŝƐ ĂůƐŽ ŝŵƉŽƌƚĂŶƚ ĚƵƌŝŶŐ ƉƌĞ-T cell 58 
development in the thymus
15 ?W ? ? ?ɷ, which is the focus of this review, is expressed highly both in 59 
lymphocytes and myeloid cells and is activated by antigen receptors, costimulatory, cytokine 60 
receptors and growth factor receptors
8
. 61 
Class I PI3Ks catalyse phosphorylation of PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3 (PIP3), which acts 62 
as a membrane tether for cell signalling proteins with pleckstrin homology (PH) domains. Prominent 63 
among these are PDK1 and AKT, which act in concert to phosphorylate substrates such as the FOXO 64 
transcription factors (which become inactivated) and regulators of the mTOR complex 1 (which 65 
becomes activated). In lymphocytes, BTK and ITK are PIP3-responsive tyrosine kinases that 66 
contribute to the activation of phospholipase C-ŐĂŵŵĂ  ?W>ɶ ? ĂŶĚ ŽƚŚĞƌ ĚŽǁŶƐƚƌĞĂŵ ƐŝŐŶĂůůŝŶŐ67 
proteins (Figs 1, 2). The lipid phosphatase PTEN converts PIP3 back to PtdIns(4,5)P2 
8
.  68 
Class IA PI3K regulatory subunits are encoded by three different genes (PIK3R1, PIK3R2 and 69 
PIK3R3)(Table 1). PIK3R1 ĞŶĐŽĚĞƐƉ ? ?ɲ ?Ɖ ? ?ɲĂŶĚƉ ? ?ɲ ?ĞĂĐŚĨƌŽŵan alternative transcription start 70 
3 
3 
 
site), PIK3R2 encodes p85E, and PIK3R3 ĞŶĐŽĚĞƐ Ɖ ? ?ɶ 16. These regulatory subunits have SH2 71 
domains, which bind phosphorylated YXXM motifs of cell surface receptors and membrane-72 
associated proteins. Ɖ ? ?ɲ ? Ɖ ? ?ɲ ? Ɖ ? ?ɲ ĂŶĚ Ɖ ? ?ɴ ĂƌĞ ǁŝĚĞůǇ ĞǆƉƌĞƐƐĞĚ ? ǁŚĞƌĞĂƐ Ɖ ? ?ɶ ŝƐ ŵĂŝŶůǇ 73 
expressed in the brain and testes 
16
. ŶǇŽĨƚŚĞĐůĂƐƐ/W/ ?<ƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚƐĐĂŶďŝŶĚƚŽƉ ? ? ?ɲ ?74 
Ɖ ? ? ?ɴŽƌƉ ? ? ?ɷǁŝƚŚŽƵƚĂƉƉĂƌĞŶƚƐĞůĞĐƚŝǀŝƚǇ ? For simplicity, we refer to the different heterodimeric 75 
ƉƌŽƚĞŝŶƐ ĂƐ W/ ?<ɲ ? W/ ?<ɴ ? W/ ?<ɷ Žƌ W/ ?<ɶbased on the constituent p110 subunit. W/ ?<ɷ ŝƐ ďĞƐƚ76 
ƵŶĚĞƌƐƚŽŽĚƚŽĐŽŵƉƌŝƐĞƉ ? ?ɲǁŝƚŚƉ ? ? ?ɷ ?ďƵƚĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶƉ ? ? ?ɷand any of the other class 77 
IA PI3K regulatory subunits is also possible. /ƚ ŝƐ ĂůƐŽ ŝŵƉŽƌƚĂŶƚ ƚŽ ƌĞĐŽŐŶŝƐĞ ƚŚĂƚ Ɖ ? ?ɲ ŚĂƐ ŵĂŶǇ78 
Ɖ ? ? ?ɷ-ŝŶĚĞƉĞŶĚĞŶƚĨƵŶĐƚŝŽŶƐĂƐŝƚĐĂŶĂůƐŽďŝŶĚƉ ? ? ?ɲĂŶĚƉ ? ? ?ɴ16. 79 
 The class IA PI3K regulatory subunits influence the p110 catalytic subunits in three ways (Fig 3)
17
: 80 
1) they prevent proteolytic degradation of p110 81 
2) they inhibit p110 catalytic activity 82 
3) recruit p110 to tyrosine phosphorylated proteins at the plasma membrane  83 
KŶĐĞƚŚĞƉ ? ?ɲ^, ?ĚŽŵĂŝŶƐĂƌĞĞŶŐĂŐĞĚďǇƉŚŽƐƉŚŽƚǇƌŽƐŝŶĞƐ ?ƚŚĞŝŶŚŝďŝƚŽƌǇĐŽŶƚĂĐƚƐǁŝƚŚƉ ? ? ?ĂƌĞ84 
relieved
17
. Thus, mutations in the PIK3R1 gene can influence PI3K activity by allowing degradation of 85 
p110 or diminishing its recruitment to receptors (PIK3R1 null or LOF mutations), or by releasing the 86 
inhibition of p110 (PIK3R1 GOF mutations)(Fig. 3) ?/ŶĂĚĚŝƚŝŽŶƚŽƚŚĞƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚƐ ?Ɖ ? ? ?ɲĂŶĚ87 
Ɖ ? ? ?ɷĐĂŶďŝŶĚZĂƐ ?ǁŚĞƌĞĂƐƉ ? ? ?ɴďŝŶĚƐƚŽZĂĐŽƌĚĐ ? ? ?dŚĞƐĞƐŵĂůů'dWĂƐĞƐŚĞůƉƚĞƚŚĞƌƉ ? ? ?ƚŽ88 
the membrane once recruited to a receptor via its regulatory subunit
17, 18
.  89 
W/ ?<ɷŝŶŝŵŵƵŶĞĐĞůůĨƵŶĐƚŝŽŶ PůĞƐƐŽŶƐĨƌŽŵŵŽƵƐĞƐƚƵĚŝĞƐ 90 
Prior to the description of APDS, most our knowledge of ƚŚĞƌŽůĞŽĨW/ ?<ɷŝŶŝŵŵƵŶŝƚǇĂŶĚŝŶĨĞĐƚŝŽŶ91 
was based on genetic and pharmacological studies using mouse models. APDS GOF mutations 92 
increase basal and stimulated PIP3 levels and PIP3-dependent signalling cascades in patient-derived 93 
lymphocytes
1-4
, and the study of these patients may give us new insights into how the balance of 94 
PI3K activity regulates immune cellular functions. Herein we summarise what these studies in mice 95 
have taught us, before describing the immunological phenotypes of human patients with mutations 96 
ŝŶƉ ? ?ɲŽƌƉ ? ? ?ɷ ? 97 
>ŽƐƐŽĨĨƵŶĐƚŝŽŶŽĨW/ ?<ɷŝŶŵŽƵƐĞĐĞůůƐ 98 
In mice, early B cell development in the bone marrow is only ŵŝůĚůǇĂĨĨĞĐƚĞĚďǇƚŚĞůŽƐƐŽĨƉ ? ?ɲŽƌ99 
Ɖ ? ? ?ɷ19-23, while ĐŽŵďŝŶĞĚůŽƐƐŽĨƉ ? ? ?ɲĂŶĚƉ ? ? ?ɷůĞĂĚƐƚŽĂŶĞĂƌĐŽŵƉůĞƚe block at the pro-B cell 100 
stage
24
. Nevertheless, mice lacking tŚĞƉ ? ?ɲŽƌƉ ? ? ?ɷƐƵďƵŶŝƚƐhave fewer follicular B cells, lack 101 
marginal zone (MZ) and peritoneal B1 B cells, have reduced serum immunoglobulins, and respond 102 
poorly to vaccination
19-23 ?W/ ?<ɷĐŽƵƉůĞƐZactivation to both PIP3 production and downstream 103 
signalling events (Fig 1). W/ ?<ɷ-deficient B cells fail to respond to mitogenic stimuli, but undergo 104 
class-switching (CSR) [G] in response to IL-4 and LPS in vitro
19-26
. However, miĐĞůĂĐŬŝŶŐƉ ? ? ?ɷ105 
selectively in B cells are competent to produce high-affinity IgG antibodies in response to 106 
immunisation with NP-CGG (T cell-dependent, TD antigen [G])
27
 (but as we shall see later, germline-107 
ůŽƐƐŽĨƉ ? ?ɲŽƌƉ ? ? ?ɷůĞĂĚƐƚŽĂƚƚĞŶƵĂƚĞĚdĂŶƚŝďŽĚǇƌĞƐƉŽŶƐĞƐ ? ?W/ ?<ɷactivity intrinsic to B cells is 108 
required for T cell-independent (TI) antibody responses, however. This may be due in part to loss of 109 
B1 and MZ B cell subsets (which are the dominant B cell subsets that respond to TI antigens) in 110 
W/ ?<ɷ-deficient mice21, 22, 27, 28. 111 
ŽŶƐĞƋƵĞŶĐĞƐŽĨŚǇƉĞƌĂĐƚŝǀĞW/ ?<ɷƐŝŐŶĂůůŝŶŐŝŶĐĞůůƐŝŶŵŝĐĞ 112 
While there are several mouse models of LOF mutations in W/ ?<ɷ, the phenotype of the GOF 113 
mutation in mouse W/ ?<ɷ remains to be described. We can however, make inferences from other 114 
4 
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models of hyperactive PI3K signalling in which Pten or Foxo is ablated in the germline or specifically 115 
in B cells or from mice expressing a membrane-bound form ŽĨƉ ? ? ?ɲŝŶĐĞůůƐ. FOXO transcription 116 
factors regulate the expression of genes involved in immunoglobulin gene recombination and 117 
development such as RAG1, RAG2, IKAROS and IL7ɲ(Fig 1)29-31. Failure to undergo VDJ 118 
recombination because of elevated PI3K signalling can lead to a partial block during B cell 119 
development in the bone marrow
29, 30
. In addition, elevated PI3K signalling can increase the 120 
sensitivity of developing B cells to negative selection by self antigens
32
. Interference with RAG 121 
expression and/or negative selection may lead to the development of B cells with aberrant 122 
phenotypes, as discussed later for APDS patients. 123 
Activation-Induced Cytidine Deaminase (AID) is the master regulator of CSR and somatic 124 
hypermutation [G] (SHM) 
33
.  Deletion of Pten or Foxo1 in B cells impairs Ig class switching
26, 30, 34, 35
, 125 
demonstrating that increased PI3K signalling in B cells antagonises this process. In Foxo1-deficient B 126 
cells activated in vitro, impaired CSR is partially due to negative regulation of AID transcription 127 
through the PI3K-FOXO1-AID axis; however, inefficient CSR was still observed in Pten-deficient B cells 128 
in the presence of ectopic AID, suggesting that PI3K signalling also regulates CSR by affecting AID 129 
function at the post-transcriptional level
26, 34, 35
. During the germinal centre (GC) reaction, B cells 130 
cycle between the light zone and dark zone. B cells interact with cognate T cells in the light zone, and 131 
if they receive the appropriate signals, undergo CSR and then traffic to the dark zone where they 132 
proliferate and undergo somatic hypermutation
36
. When, Foxo1 was deleted specifically in (GC) [G] B 133 
cells, CSR was impaired despite normal AICDA transcription and AID protein expression. This 134 
suggests that either Foxo1 regulates targeting of AID to the immunoglobulin gene locus, that Foxo1 135 
targets other genetic loci required for CSR and SHM, or that Foxo1 deletion in the GC affects 136 
expression of other proteins required for CSR
37, 38
. Moreover, Foxo1 ablation or induction of PI3K 137 
activity in germinal centre B cells led to loss of GC dark zones due to aberrant trafficking of B cells at 138 
least in part as a consequence of lost expression of Cxcr4 which is a target of Foxo1
37, 38
. Hence, 139 
failure to expand antigen-specific B cells that have undergone selection in the GC light zone is an 140 
additional cause of impaired high affinity class-switched antibody production.  141 
Together, these findings contrast the effects of impaired PI3K signalling versus unrestrained PI3K 142 
signalling in B cells. W/ ?<ɷĚĞĨŝĐŝĞŶĐǇŝŶŵĂƚƵƌĞĐĞůůƐŝŵƉĂŝƌƐTI antibody responses but does not 143 
affect CSR or SHM
27
. By contrast, hyperactivation of PI3K signalling in mature B cells interferes with 144 
CSR and SHM and expansion of antigen-specific B cells in the GC dark zones (Fig 4) 
26, 34, 35
. 145 
W/ ?<ɷŝƐƌĞƋƵŝƌĞĚĨŽƌŵŽƵƐĞ ?+ T cell differentiation and Treg function 146 
/ĨW/ ?<ɷ-deficient B cells can undergo CSR, then why ĚŽW/ ?<ɷ-deficient mice fail to respond to T cell-147 
dependent vaccines? The answer relates to the provision of T cell help for B-cell development and 148 
immunoglobulin class switching. ICOS is a T cell costimulatory receptor and a potent activator of 149 
W/ ?<ɷ ?Mutant mice in which ICOS has been uncoupled ĨƌŽŵW/ ?<ɷ fail to develop follicular helper T 150 
cells (Tfh) [G] 
39 ?^ŝŵŝůĂƌůǇ ?ĚĞůĞƚŝŽŶŽĨƚŚĞƉ ? ? ?ɷƐƵďƵŶŝƚŝŶdcells interferes with the development of 151 
Tfh, leading to dramatic attenuation of T cell-dependent immune responses, including CSR and SHM 152 
by the B cells activated in absence of Tfh
27
. These results highlight a dual role for W/ ?<ɷŝŶĂŶƚŝďŽĚǇ153 
production: inactivation of P/ ?<ɷin B cells leading to activation of Foxo transcription factors is a 154 
prerequisite for CSR and SHM
26, 34, 35
, ǁŚĞƌĞĂƐƚŚĞĂĐƚŝǀĂƚŝŽŶŽĨW/ ?<ɷ ŝŶdĨŚ ŝƐƉƌĞƌĞƋƵŝƐŝƚĞĨŽƌƚŚĞ155 
provision of B cell help supporting CSR and SHM
27
.  156 
Naïve CD4 T cell differentiation towards Th2, Th17 and Th1 lineages is delayed or attenuated when 157 
W/ ?<ɷ ŝƐ ŝŶŚŝďŝƚĞĚ40-42. This may reflect a key role for Foxo transcription suppressing Th 158 
differentiation, for instance by suppressing the Ifng gene
43
, as well as the requirement for mTOR 159 
5 
5 
 
activity to promote Th differentiation
44
. A reduction in Th2 responses underpins the resistance of 160 
W/ ?<ɷ-deficient mice to experimental asthma, despite elevated IgE levels25, 45. Reduced Th17 161 
ƌĞƐƉŽŶƐĞƐŵĂǇƉƌŽƚĞĐƚW/ ?<ɷ-deficient mice from experimental autoimmune encephalitis, a mouse 162 
model of multiple sclerosis
46
. Although W/ ?<ɷ ĚĞĨŝĐŝĞŶƚ ŵŝĐĞ ƌĂŝƐĞ ĂŶ ŝŵƉĂŝƌĞĚdŚ ? ƌĞƐƉŽŶƐĞ ĂĨƚĞƌ163 
infections with Leishmania monocytogenes, W/ ?<ɷ-deficient mice control Leishmania infections more 164 
effectively than WT mice, likely due to defects in a regulatory immune cell population
47
.  165 
W/ ?<ɷ ŝŶŚŝďŝƚŝŽŶ ŝŶƚĞƌĨĞƌĞƐ ǁŝƚŚFoxp3+ regulatory T cell (Treg) homeostasis and function48 ? W/ ?<ɷ-166 
deficient mice develop colitis because of inappropriate activation of effector T cells by gut microbes 167 
ĂŶĚW/ ?<ɷ-deficient Treg fail to suppress experimental colitis22, 48. WĂƚŝĞŶƚƐƚĂŬŝŶŐƚŚĞW/ ?<ɷŝŶŚŝďŝƚŽƌ168 
Idelalisib also develop colitis, probably in part as a result of reduced Treg function
49, 50
. However, 169 
W/ ?<ɷ-ĚĞĨŝĐĞŶƚŵŝĐĞĂŶĚŵŝĐĞůĂĐŬŝŶŐƉ ? ? ?ɷŽŶůǇŝŶdƌĞŐŵŽƵŶƚĂŵŽƌĞĞĨĨĞĐƚŝǀĞŝŵŵƵŶĞƌĞƐƉŽŶƐĞ170 
against cancer than do WT mice
51
. As with antibody production, these data highlight the dual nature 171 
ŽĨW/ ?<ɷ, which is required both for optimal cytokine production by effector T cells and for effective 172 
Treg-mediated suppression. tŚĞƚŚĞƌW/ ?<ɷŝŶŚibition results in impaired or enhanced cell-mediated 173 
immune responses is context dependent and therefore difficult to predict (Fig 4). /ŶƚĞƌĞƐƚŝŶŐůǇ ?W/ ?<ɷ174 
inactivation results in hyper-responsiveness to toll like receptor ligands in DC and macrophages 175 
resulting in increased IL-12 production, which may further contributed to increased cell-mediated 176 
ŝŵŵƵŶĞƌĞƐƉŽŶƐĞƐƵƉŽŶ>K&ŽĨW/ ?<ɷ52.   177 
W/ ?<ɷƌĞŐƵůĂƚĞƐŵŽƵƐĞ ?+ T cell effector functions 178 
W/ ?<ɷ-deficient CD8+ T cells stimulated in vitro are characterised by reduced abundance of mRNAs 179 
associated with inflammation and cytotoxicity, such as /&Eɶ ?'ǌŵď and Pfn51, 53, 54. By contrast, the 180 
expression of genes regulating the homing of T cells to the lymph nodes, such as Sell (CD62L), Ccr7 181 
and Klf2 are ŝŶĐƌĞĂƐĞĚŝŶW/ ?<ɷ-deficient CD8+ T cells stimulated in vitro55. Thus, W/ ?<ɷcan regulate 182 
the homeostatic trafficking of T cells to the lymph nodes and contributes to the reprogramming of 183 
CD8
+
 T cells to acquire full effector functions and migrate to peripheral tissues. 184 
W/ ?<ɷ ŝƐ ƌĞƋƵŝƌĞĚfor optimal magnitude of CD8+ T cell responses in vivo53, 56. NevertheůĞƐƐ ?W/ ?<ɷ-185 
deficient CD8
+
 T cells can respond to infection and become fully differentiated cytotoxic T cells that 186 
ƉƌŽĚƵĐĞ/&EɶĂŶĚŐƌĂŶǌǇŵĞƌĞƋƵŝƌĞĚĨŽƌƚŚĞŬŝůůŝŶŐŽĨǀŝƌƵƐ-infected cells or tumours; this suggests 187 
that the transcriptional defects described in vitro can be, at least in part, be overcome by strong 188 
inflammatory stimuli in vivo
51, 53
. Moreover, long-term CD8
+
 T cell memory responses are intact in 189 
W/ ?<ɷ-deficient mice53. This is in part because during recall responses, the generation of CD8 effector 190 
T cells is reduced, whereas the generation of long-term memory T cells in the lymph nodes and bone 191 
marrow is preserved
53
. Similarly, the inhibition of the downstream kinase mTOR with low-dose 192 
rapamycin during vaccination or infection augments CD8 T cell memory at the expense of effector 193 
CD8+ T cells
57
. Hence, by promoting mTOR activity, W/ ?<ɷƐŬĞǁƐ ?+ T cell differentiation in favour 194 
of effector T cells, but antagonises the generation of memory T cells. Thus ?ƐƚƌŽŶŐW/ ?<ɷĂĐƚŝǀŝƚǇ ŝƐ195 
associated with effector T cell differentiation, whereas the maintenance of T cell memory requires 196 
suppression of PI3K signalling (Fig 4). 197 
Consequences of hyperactive PI3K signalling in mouse T cells 198 
dŚĞĐŽŶƐĞƋƵĞŶĐĞŽĨW/ ?<ɷŚǇƉĞƌĂĐƚŝǀĂƚŝŽŶŝŶŵŽƵƐĞdĐĞůƐĐĂŶďĞŝŶĨĞƌƌĞĚĨƌŽŵĞǆƉĞƌŝŵĞŶƚƐƵƐŝŶŐ199 
Pten-deficient or Foxo-deficient T cells. Pten deletion in early T cell development leads to immature 200 
T cell lymphoma and a hyperactivated T cell phenotype, characterised by increased secretion of 201 
effector T cell cytokines and autoimmunity
58
. Similar results were observed in a mouse expressing a 202 
ĚĞůĞƚŝŽŶŵƵƚĂƚŝŽŶŽĨƉ ? ?ɲǁŚŝĐŚůĂĐŬĞĚŝŶŚŝďŝƚŽƌĐŽŶƚĂĐƚƐǁŝƚŚƉ ? ? ?59. Deleting Pten in mature 203 
CD4
+
 T cells also engenders enhanced cytokine production and Th function, but did not induce T cell 204 
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transformation or autommunity
60
. Furthermore, genetic loss of Foxo1 leads to the absence of 205 
memory CD8
+
 T cells after infection
61
. Together, these data indicate a unique sensitivity ƚŽW/ ?<ɷ-206 
dependent T cell transformation during ƚŚǇŵŝĐĚĞǀĞůŽƉŵĞŶƚ ?ǁŚĞƌĞW/ ?<ɷƐŝŐŶĂůůŝŶŐŵĂǇĂůƐŽaffect 207 
central tolerance to self-peptides. Overall, these studies suggest that unrestrained PI3K signalling in 208 
T cells lowers their threshold of activation. 209 
ůƚĞƌĂƚŝŽŶƐŝŶW/ ?<ɷƐŝŐŶĂůůŝŶŐůĞĂĚƐƚŽW/ƐŝŶŚƵŵĂŶƐ 210 
Both LOF and GOF mutations that cause PID in humans have been described. Our understanding of 211 
the underpinning causes of these PIDs has been greatly aided by the investigations using mouse 212 
models described in the previous section, but have also furthered and challenged our understanding 213 
ŽĨW/ ?<ɷ ?ĂƐŚŝŐŚůŝŐŚƚĞĚŝŶŽǆ2 and described further below. 214 
>ŽƐƐŽĨĨƵŶĐƚŝŽŶŽĨƉ ? ?ɲŽƌƉ ? ? ?ɷŝŶŚƵŵĂŶƐ 215 
Ɛ ǁŝƚŚ ŵŽƵƐĞ d ĐĞůůƐ ? ŝŶŚŝďŝƚŝŽŶ ŽĨ W/ ?<ɷ ĂĐƚŝǀŝƚǇ ŝŶ ŚƵŵĂŶ d ĐĞůůƐ ƐƵƉƉƌĞƐƐĞĚ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ216 
effector cytokines ƐƵĐŚ ĂƐ /&Eɶ ? />-4 and IL-17 41. A single patient with a homozygous PIK3R1 217 
mutation that generated a premature ƐƚŽƉ ĐŽĚŽŶ  ?ƌĞƐƵůƚŝŶŐ ŝŶ ƚŚĞ ůŽƐƐ ŽĨ Ɖ ? ?ɲ ĂŶĚ ŵĂƌŬĞĚůǇ218 
ĚĞĐƌĞĂƐĞĚ ĞǆƉƌĞƐƐŝŽŶ ŽĨ Ɖ ? ? ?ɷ ? ƉƌĞƐĞŶƚĞĚ with recurrent pneumonia associated with 219 
agammaglobulinemia and severe B cell lymphopenia due to a block in early B cell development
10
. 220 
Development of colitis in this patient was attributed to antibody-deficiency and consequence 221 
outgrowth of gut pathogens, but could also be due to Treg deficiency
10
. Similarly, one patient lacking 222 
Ɖ ? ? ?ɷĂƐĂƌĞƐƵůƚŽĨƚŚĞŝŶŚĞƌŝƚĂŶĐĞŽĨƚǁŽĚŝĨĨĞƌĞŶƚŶŽŶ-functional alleles has been described, and 223 
this patient presented with sinopulmonary infections, septic arthritis, inflammatory bowel disease 224 
and autoimmune hepatitis, associated with hypogammaglobulinemia
9
.  Loss of p110G was again 225 
associated with severe B cell lymphopenia and fewer memory T cells
9
.  Thus, the two reported 226 
patients with loss of PI3KG suffer infections associated with the lack of B cells.  Interestingly, in mice, 227 
a complete block in B cell development and severe mature B cell lymphopenia are only observed 228 
ǁŚĞŶ ďŽƚŚ ƚŚĞ Ɖ ? ? ?ɲ ĂŶĚ Ɖ ? ? ?ɷ ĂƌĞ ŝŶĂĐƚŝǀĂƚĞĚ ŝŶ ƚŚĞ  ĐĞůůůŝŶĞĂŐĞ24, suggesting a redundancy 229 
between these isoforms in mice that is not reflected in humans. The inflammatory and autoimmune 230 
manifestations ŝŶW/ ?<ɷ-deficient humans underscore the importance of PI3KG in maintaining self-231 
tolerance, possibly associated with reduced Treg function. W/ ?<ɷŝƐĂůƐŽƌĞƋƵŝƌĞĚĨŽƌƚŚĞŐĞŶĞƌĂƚŝŽŶ232 
of reactive oxygen species (ROS) [G] ďǇŚƵŵĂŶŶĞƵƚƌŽƉŚŝůƐĂŶĚƚƌĞĂƚŵĞŶƚŽĨƉĂƚŝĞŶƚƐǁŝƚŚƚŚĞW/ ?<ɷ233 
inhibitor idelalisib can lead to neutropenia and increased risk of infections 
49, 62
.  234 
ĐƚŝǀĂƚŝŶŐW/ ?<ɷŵƵƚĂƚŝŽŶƐƚŚĂƚƵŶĚĞƌůŝĞŚƵŵĂŶW  ^235 
In 2013, groups in Cambridge (UK) and Bethesda (US) reported whole-exome sequencing studies of 236 
patients with uncharacterised PID, which revealed causal heterozygous activating mutations in 237 
PIK3CD
1, 2
. The UK patients were identified by screening cohorts of PID patients with a high 238 
frequency of recurrent chest infections and bronchiectasis, features suggestive of antibody 239 
deficiency, although frequent herpes viral infections and an increased proportion of effector T cells 240 
were also noted
1
. The US cohort were identified on the basis of persistent viremia with herpes-241 
family viruses, which are commonly associated with altered T cell or NK cell function, in addition to 242 
frequent airway infections
2
. Because both B cells and T cells are affected, APDS should be 243 
characterised as a combined immunodeficiency
1-5
.  244 
This immunodeficiency had previously been noted in a Taiwanese boy by targeted sequencing of the 245 
PIK3CD gene in children with B cell immunodeficiency, although the GOF nature of the mutation was 246 
not elucidated
63
. Subsequently, a number of additional studies have identified APDS patients with 247 
mutations in PIK3CD
5, 7, 64-67
 or PIK3R1
6, 68-71
. Patients with GOF mutations in either of these genes 248 
appear to largely phenocopy each other, despite the fact that PIK3R1 is ubiquitously expressed and 249 
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can pair with other ĐĂƚĂůǇƚŝĐ ƐƵďƵŶŝƚƐ ďĞƐŝĚĞƐ Ɖ ? ? ?ɷ. There is some evidence for effects of the 250 
PIK3R1 mutation outside the immune system (e.g, short stature, Box 1)
72
, but detailed analyses of 251 
effects ŽĨ ƚŚŝƐ Ɖ ? ?ɲ ƚƌƵŶĐĂƚŝŽŶon Ɖ ? ? ?ɲor Ɖ ? ? ?ɴhave not yet been reported. In order to 252 
distinguish the PID caused by PIK3CD and PIK3R1 mutations respectively, the terms APDS1/PASLI-CD 253 
and APDS2/PASLI-R1 have been proposed
1-4
. Patients with APDS1 or APDS2 resemble each other 254 
biochemically and clinically, suggesting that the pathological features are a consequence of aberrant 255 
ĂŶĚŚǇƉĞƌĂĐƚŝǀĞW/ ?<ɷƐŝŐŶĂůůŝŶŐ1-4. Here we use the generic terms APDS unless referring specifically 256 
to either. A milder form of APDS-like immunodeficiency has been described in Cowden disease, 257 
caused by heterozygous loss of the PIP3 phosphatase PTEN, though the increases in PIP3 from these 258 
patient T cells was less obvious than observed in APDS
73
.  259 
The most frequent mutation in PIK3CD (c.3061G>A) encodes a glutamic acid for lysine substitution at 260 
position 1021 (E1021K) of p110ɷ (Table 1). To date, this mutation has only been found in APDS 261 
patients and their affected family members but not among healthy unrelated subjects
1
. Patients 262 
with the E1021K mutation have been found across continents and ethnicities. Genetic analysis 263 
showed no founder effect, demonstrating that E1021K is a recurrent mutation that appeared de 264 
novo independently in multiple unrelated families
1
. 265 
Increased lipid kinase activity of Ɖ ? ? ?ɷ carrying the E1021K mutation was shown using recombinant 266 
proteins in vitro and by measuring PIP3 and AKT phosphorylation in patient-derived T cells
1, 2
. The 267 
E1021K mutation is located in the C-terminal ůŽďĞŽĨ ƚŚĞŬŝŶĂƐĞĚŽŵĂŝŶŽĨƉ ? ? ?ɷ ?ƐŝŵŝůĂƌůǇ ƚŽ ƚŚĞ268 
oncogenic H1047R ŵƵƚĂƚŝŽŶŽĨƉ ? ? ?ɲ, and enhances the membrane-association of Ɖ ? ? ?ɷin vitro, 269 
facilitating more effective phosphorylation of its lipid substrate PIP2, hence lowering the threshold of 270 
ĂĐƚŝǀĂƚŝŽŶĨŽƌW/ ?<ɷ1, 17 (Fig 3). Other missense Ɖ ? ? ?ɷ mutations, N334K, C416R and E525K, have also 271 
been shown to cause APDS, although they are less frequent than E1021K
2
(Table 1). Interestingly, 272 
GOF mutations of the homologous amino acid residues of p110D (N345, C420 and E545, 273 
respectively), have been identified in tumors (http://www.sanger.ac.uk/genetics/CGP/cosmic/) and 274 
are thought to interfere with the inhibitory contacts imposed by p85 and hence increase p110 lipid 275 
kinase activity
17
; by implication a similar mechanism leads to enhanced PIP3 accumulation in cells 276 
from APDS patients with the equivalent mutations and hence the immune modulation seen in APDS 277 
(Fig 3). APDS is thus distinct from most other PIDs in that it is the hyperactivation of signaling 278 
pathways, rather than inhibition, that leads to immune dysfunction. This distinction offers a 279 
therapeutic opportunity (see below). 280 
Heterozygous splice site mutation before exon 11 of the PIK3R1 gene leads to an in-frame fusion of 281 
exon 10 with exon 12 resulting in the deletion of 42 amino acids in p85D (del p.434  W 475), p55D and 282 
p50D3, 4(Fig 3). These amino acids lie in the inter-SH2 domain that regulates activity of the catalytic 283 
p110 subunits
74
. Oncogenic mutations in this region result in mutant proteins that can bind p110 284 
subunits but are less effective at inhibiting their enzymatic activity
74, 75
. Similar to mutations in the 285 
Ɖ ? ? ?ɷƐƵďƵŶŝƚ ?ƚŚŝƐŝƐƚŚŽƵŐŚƚƚŽůŽǁĞƌƚŚĞƚŚƌĞƐŚŽůĚŽĨĂĐƚŝǀĂƚŝŽŶĨŽƌW/ ?<ɷ. The mutant p85Ddel434 W286 
475
 protein (Fig 3 ?ȴǆ ? ? ? could stabilize Ɖ ? ? ?ɷ, which was expressed at near normal levels in patient 287 
cells, but its inhibitory function was impaired, leading to increased W/ ?<ɷĂĐƚŝǀŝƚǇ3, 4.  288 
Thus, a number of different mutations in PIK3R1 or PIK3CD lead to increased activity of the 289 
Ɖ ? ?ɲ ?Ɖ ? ? ?ɷ ŚĞƚĞƌŽĚŝŵĞƌŝĐ ƉƌŽƚĞŝŶ ? ĞŝƚŚĞƌ ďǇ ĚŝƐƌƵƉƚŝŶŐ ŝŶŚŝďŝƚŽƌǇ ĐŽŶƚĂĐƚƐ ďĞƚǁĞĞŶ Ɖ ? ?ɲ ĂŶĚ290 
Ɖ ? ? ?ɷ Žƌ ďǇ ŝŶĐƌĞĂƐŝŶŐ ĂĨĨŝŶŝƚǇ ĨŽƌ ƚŚĞ ƉůĂƐŵĂ ŵĞŵďƌĂŶĞ ?ƉƌŽŵŽƚŝŶŐ ŝŶƚĞƌĂĐƚŝŽŶ ǁŝƚŚ ŝƚƐ ůŝƉŝĚ291 
substrate and hence facilitating phosphorylation. 292 
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ĐƚŝǀĂƚŝŶŐW/ ?<ɷŵƵƚĂƚŝŽŶƐůĞad to Impaired B cell function and vaccine responses  293 
Immunoglobulin levels in APDS are variable, ranging from isolated specific antibody deficiency or IgG 294 
subclass deficiency to severe hypogammaglobulinemia [G], often with increased IgM levels. In one 295 
cohort, 10% of a heterogeneous PID cohort who suffered recurrent infections [G] were found to 296 
have APDS
1
, whereas in a second cohort of mainly antibody-deficient PID patients, fewer than 1% 297 
had PIK3CD mutations
5
.   298 
Most APDS patients have increased proportions of circulating transitional B cells [G], reduced class 299 
switched memory B cells, and impaired vaccine responses
1,3
. In vitro, patient-derived B cells showed 300 
impaired CSR (consistent with the observed tendency to reduced IgG and increased IgM levels), but 301 
in contrast to the findings in mouse cells, this was not associated with reduced AID mRNA levels
2
. As 302 
noted above, it is possible that PI3K regulates AID function by post-transcriptional mechanisms as 303 
well as by regulation of expression
35
. Alternatively, the defective CSR in APDS patients could be due 304 
to defects in germinal centre Tfh cells
76
, aberrant B cell maturation and/or defective migration of B 305 
cells during the germinal centre reaction in the spleen, as shown for Foxo-deficient B cells in mice
37, 
306 
38
. The basis for the increased percentage of circulating transitional B cells in APDS patients remains 307 
incompletely understood, but is likely to be a consequence of impaired B cell maturation and/or an 308 
increased propensity for mature B cells to undergo apoptosis
1
. These findings are in marked contrast 309 
with the dramatic loss of the B cells and agammaglobulinemia seen in the rare patients with LOF 310 
mutations in PIK3R1 or PIK3CD.  311 
Encapsulated bacteria (Haemophilus influenzae and Streptococcus pneumoniae) are the most 312 
frequent respiratory isolates from APDS patients (Box 1), compatible with a significant defect in 313 
antibody-mediated immunity. However, the severity of respiratory infections and consequent 314 
structural lung damage do not correlate well with total B cell numbers or extent of immunoglobulin 315 
deficiency
6, 7
 and immunoglobulin replacement therapy alone does not appear to limit progression 316 
of lung damage in APDS. One explanation for this apparent discrepancy is that W/ ?<ɷŚǇƉĞƌĂĐƚŝǀĂƚŝŽŶ317 
causes additional defects (such as the altered T cell functions described above, or innate immune 318 
cell dysfunction) not directly related to antibody production that also contribute to respiratory 319 
bacterial infections. &Žƌ ŝŶƐƚĂŶĐĞ ? W/ ?<ɷ ŚĂƐ ďĞĞŶ ƐŚŽǁŶ ƚŽpromote ROS production by human 320 
neutrophils which could cause collateral damage if excessively produced during infections
62
. 321 
However, analysis of APDS patient neutrophils did not reveal obvious increase in ROS, or indeed in 322 
PIP3 production, in response to stimulation with microbial peptides
1
. However, Staphylococcal skin 323 
infections and abscess formation
1, 65
, as well as defective killing of mycobacteria by macrophages 324 
from an APDS patient
64
 suggest abnormalities may indeed exist in the innate immune system which 325 
remain to be more completely qualified. Increased PI3K activity has been shown to compromise 326 
neutrophil migratory accuracy, and hence prolong the tissue-transit time, leading to increased 327 
opportunities for bystander tissue injury mediated by surface-associated neutrophil proteases
48
. 328 
Hence a wide range of impaired cellular functions, affecting innate and adaptive immune responses, 329 
may contribute to recurrent infection and bronchiectasis in APDS. 330 
ĐƚŝǀĂƚŝŶŐW/ ?<ɷŵƵƚĂƚŝŽŶƐĐĂƵƐĞdĐĞůůƐĞŶĞƐĐĞŶĐĞ 331 
Peripheral blood analysis revealed a preponderance of effector-type T cells with a severe reduction 332 
in naïve T cells
1-4
. Freshly isolated peripheral blood cells demonstrated reduced secretion of 333 
cytokines and increased apoptosis upon TCR restimulation
1-3
. Unexpectedly, acute W/ ?<ɷŝŶŚŝďŝƚŝŽŶin 334 
APDS patient cells reduced ƚŚĞŝŶĚƵĐƚŝŽŶŽĨĂƉŽƉƚŽƐŝƐ ?ƐƵŐŐĞƐƚŝŶŐƚŚĂƚW/ ?<ɷƐŝŐŶĂůůŝŶŐĐŽŶƚƌŝďƵƚĞs to 335 
previously unappreciated pro-apoptotic pathways in APDS T cells
1, 3
. However, T cell blasts that had 336 
escaped apoptosis and expanded after activation in vitro showed increased production of IFNɶ ? TNFɲ 337 
and granzyme B 
2
. Thus, chronic hyperactivation of PI3K signalling promotes T cell differentiation 338 
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into terminal effectors with increased sensitivity to TCR-induced cell death and derangements in 339 
cytokine secretion.  340 
 341 
Notably, the expression of CD57, a surface marker on CD8 T cells in a senescent state due to extreme 342 
telomere shortening
77
, was consistently high on patient cells
2, 4
. Subsequent analyses confirmed 343 
shortening of telomere length in APDS patient lymphocytes
4
, suggesting T cell senescence [G] 344 
contributes to immune dysfunction in APDS patients. Patients free from viraemia also presented 345 
with increased CD57
+
CD8 T cells
2
; therefore, T cell senescence in APDS is likely to be distinct from T 346 
cell exhaustion driven by chronic viral infections. T cell senescence from telomere shortening results 347 
in cell cycle arrest while maintaining most other responses to antigen
78
, whereas T cell exhaustion 348 
from chronic antigen stimulation results in upregulation of co-inhibitory receptors that broadly 349 
dampen TCR signalling and antigen responsiveness
79
. These findings point to in-vivo 350 
hyperproliferation (consistent with enlarged spleen and lymph nodes) as the underlying cause of the 351 
T cell senescence and short telomeres in APDS patients and support the connection between cell 352 
division and T cell effector differentiation.  353 
 354 
T cells from APDS patients exhibit increased activity of mTOR
2
, a key mediator of the switch from a 355 
catabolic naïve state to an anabolic effector state during a T cell response
80
. Increased glucose 356 
uptake is also observed in T cells from APDS patients as compared to healthy subjects
2, 4
. These 357 
findings indicate changes in T cell metabolism induced by hyperactive PI3K signalling may underlie 358 
the hyperproliferation that is associated with T cell senescence in APDS patients. Further studies will 359 
be needed to determine if the elevated mTOR activity is a direct consequence of increased PI3K 360 
activity or whether it also reflects the skewed effector phenotype of T cells in APDS patients. W/ ?<ɷ361 
inhibition did reduce, but not ablate, S6 phosphorylation in APDS T cells, confirming ƚŚĂƚ W/ ?<ɷ362 
contributes to mTOR activity in these cells
4
. Unrestrained and prolonged PI3K and mTOR activity may 363 
hence drive APDS T cells towards senescence rather than allowing T cells to revert to a metabolically 364 
quiescent phenotype after antigen exposure. 365 
 366 
The main clinical manifestation of abnormal T cell function in APDS is herpes viral infection. All 367 
PIK3CD mutation patients reported by Lucas et al.
3
 experienced chronic EBV and/or CMV viremia; in 368 
other studies the occurrence of CMV/EBV was lower
1, 4-7
, although Herpes simplex virus and 369 
Varicella-zoster virus infections were also noted. These inter-study differences may reflect the case-370 
finding strategies, immune profiles or pathogen exposure. Surprisingly, given the abnormal T cell 371 
profiles, few other opportunistic infections have been reported. Some cases of problematic viral 372 
warts and Molluscum contagiosum have been identified
7
, perhaps suggesting impaired NK cell 373 
function, though this has yet to be confirmed experimentally.  374 
Treatment options for APDS 375 
As APDS patients often present with reduced IgG and/or respond poorly to vaccines, many are 376 
treated with immunoglobulin replacement therapy often supplemented with prophylactic 377 
antibiotics. While this may have been effective in some patients, it has not prevented the acquisition 378 
or progression of bronchiectasis in others even when initiated in childhood
6, 7
. Haematopoietic stem 379 
cell transplant (HSCT) is a treatment option, particularly for younger patients. HSCT could also help 380 
prevent or treat malignant B cell transformation, which occurs in 10-15% of patients. Several 381 
patients have undergone HSCT and, although significant improvements have been noted
6, 7
, the 382 
follow up of these patients is too short to make a definitive conclusion.  383 
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Rapamycin 384 
Lucas and colleagues reported one patient treated with the mTOR inhibitor rapamycin, who showed 385 
a dramatic reduction in lymphadenopathy and hepatosplenomegaly
2
. The effect of rapamycin on B 386 
cell homeostasis and humoral immune responses in APDS patients remains to be determined. It is 387 
important to keep in mind, ŚŽǁĞǀĞƌ ? ƚŚĂƚ W/ ?<ɷ ƌĞŐƵůĂƚĞƐ ŽƚŚĞƌ ƉĂƚŚǁĂǇƐbesides mTOR, and 388 
conversely, that mTOR receives input from PI3K-independent pathways
8
. Moreover, mTOR regulates 389 
the expression of Pten such that treatment of T cells with rapamycin can actually increase PI3K 390 
ƐŝŐŶĂůůŝŶŐŝŶdĐĞůůƐ ?ƉŽƚĞŶƚŝĂůůǇĞǆĂĐĞƌďĂƚŝŶŐĂƐƉĞĐƚƐŽĨŚǇƉĞƌĂĐƚŝǀĞW/ ?<ɷƐŝŐŶĂůůŝng in APDS81. 391 
W/ ?<ɷŝŶŚŝďŝƚŽƌƐ 392 
The PI3Kɷ inhibitor Idelalisib is licenced for use in chronic lymphocytic leukaemia and non-Hodgkin 393 
lymphoma
82, 83
. However, Idelalisib has a significant side-effect profile, including 394 
pneumonitis/pneumonia, transaminitis and colitis in up to 42% of patients treated
49
. Histologically 395 
the colitis is reminiscent of that seen in mice lacking functional W/ ?<ɷ, suggesting it is an on-target 396 
class-effect rather than compound-specific
49
. It is possible that APDS patients will benefit from lower 397 
ĚŽƐĞƐŽĨW/ ?<ɷ ŝŶŚŝďŝƚŽƌƐƚŚĂŶĂƌĞƌĞƋƵŝƌĞĚĨŽƌ ƚƌĞĂƚŵĞŶƚŽĨĐĞůů ůǇŵƉŚŽŵĂƐ ?ĂŶĚŚĞŶĐĞŵĂy be 398 
spared some of the more severe side effects. Another possibility is that topical administration of the 399 
W/ ?<ɷŝŶŚŝďŝƚŽƌŵĂǇavoid some of the adverse effects.  400 
dǁŽ ĐůŝŶŝĐĂů ƚƌŝĂůƐ ŽĨ W/ ?<ɷ ŝŶŚŝďŝƚŽƌƐ ŝŶ W^ ŚĂǀĞ ďĞĞŶ ĂŶŶŽƵŶĐĞĚ ƚŽ ĚĂƚĞ PNCT02435173 401 
ƐƉŽŶƐŽƌĞĚďǇEŽǀĂƌƚŝƐĨŽƌĂŶŽƌĂůW/ ?<ɷŝŶŚŝďŝƚŽƌĂŶĚNCT02593539 sponsored by GSK for an inhaled 402 
W/ ?<ɷŝŶŚŝďŝƚŽƌ ?dŽĐŽƌƌĞĐƚ systemic immune defects, including lymphoproliferation and lymphoma, 403 
an oral inhibitor is more likely to be effective; however, an inhaled inhibitor is expected to have a 404 
better safety profile and may be appropriate for patients who are primarily affected by airway 405 
infections, potentially to limit progression of bronchiectasis.  406 
Conclusions 407 
GOF mutations in PI3Kɷ ůĞĂĚƚŽĂƌĂŶŐĞŽĨdĂŶĚĐĞůůĚĞǀĞůŽƉŵĞŶƚĂůĂŶĚĨƵŶĐƚŝŽŶĂůĚĞĨĞĐƚƐ ƚŚĂƚ408 
compromise host defence, leading to recurrent bacterial and viral infections (Box 1). This 409 
ĚŝƐƚŝŶŐƵŝƐŚĞƐW^ƉĂƚŝĞŶƚƐĨƌŽŵƉĂƚŝĞŶƚƐǁŝƚŚ>K&ŽĨW/ ?<ɷǁŚŽƉƌĞƐĞŶƚǁŝƚŚŵƵĐŚŵŽƌĞƐĞǀĞƌĞ410 
cell lymphopenia and agammaglobulinemia, but not T cell senescence. In general, GOF mutations 411 
are unusual causes of immune deficiency
84 ?dŚĞƚŚĞƌĂƉĞƵƚŝĐŽƉƚŝŽŶƐĨŽƌ>K&ŽĨW/ ?<ɷŵĂǇďĞůŝŵŝƚĞĚ412 
to immunoglobulin replacement, bone marrow transplants and perhaps gene-therapy. Although 413 
these are options for APDS as well, existing (mTOR inhibitors) and emerging (PI3Kɷ ŝŶŚŝďŝƚŽƌƐ ?414 
therapeutics offer the additional possibility of correcting the biochemical defects that arise from 415 
APDS-associated mutations, and the impact of these agents is currently being explored.  416 
The fact that both LOF and GOF ŽĨW/ ?<ɷ ůĞĂĚƐ ƚŽ ŝŵŵƵŶŽĚĞĨŝĐŝĞŶĐŝĞƐŚŝŐŚůŝŐŚƚƐ ƚŚĞĐŽŶĐĞƉƚ ƚŚĂƚ417 
this pathway must be modulated precisely and dynamically for optimal immune cell function: too 418 
much, too little or the inability to turn the pathway on or off as needed, has detrimental 419 
consequences (Fig 4) 
8
. These considerations raise the possibility that aberrant PI3K signalling in 420 
immune cells may also occur in non-genetic diseases or conditions that lead to increased 421 
susceptibility to infections.  422 
Many fundamental questions remain to be answered. How common is APDS among PID patients? 423 
What are some of the genetic or environmental influences that lead to clinical heterogeneity of 424 
APDS patients? Are there mutations in other genes that lead to hyperĂĐƚŝǀĂƚŝŽŶŽĨW/ ?<ɷĂŶĚW -^425 
like syndromes? Why do APDS T cells undergo apoptosis when stimulated? Why does recurrent 426 
airway infection lead to bronchiectasis more frequently in APDS patients than in other PIDs? Can 427 
11 
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W/ ?<ɷ ŝŶŚŝďŝƚŽƌƐ ƌĞƐƚŽƌĞ ŶŽƌŵĂů ŝŵŵƵŶĞ Ĩunction in APDS? The answers to these and further 428 
questions will required more detailed analysis of APDS patient cohorts, genetic screening of larger 429 
PID cohorts, and establishment of mouse models that mimic this intriguing new disease and help 430 
evaluate different therapeutic strategies. 431 
  432 
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Table 1. PI3K subunits and APDS mutations 433 
 Catalytic 
Subunit 
Tissue Selected functions 
 Gene Protein   
Class IA PIK3CA SĮ Ubiquitous Metabolism, angiogenesis 
 PIK3CB Sȕ Ubiquitous Metabolism, neutrophil activation 
 PIK3CD Sį Haematopoietic, CNS Immunity 
     
Class IB PIK3CG SȖ Haematopoietic, heart Immunity, metabolism, cardiac 
     
     
     
 Regulatory Subunit Tissue Selected functions 
 Gene proteins(s   
Class IA PIK3R1 SĮSD
p50a 
Ubiquitous Metabolism, Immunity 
 PIK3R2 Sȕ Ubiquitous Metabolism, Immunity 
 PIK3R3 SȖ Brain, testes. Unknown 
     
Class IB PIK3R5 p101 Haematopoietic Immunity 
 PIK3R6 p84 (aka p87) Haematopoietic Immunity 
     
     
 APDS Number of cases reported References 
APDS1 PIK3CD N334K 1 2 
  C416R 2 65 
  E525K 7 2 
  E1021K 60 1, 2, 5, 7, 63-67 
     
APDS2 PIK3R1 del p.434-475 43 3, 4, 6, 68-72 
 434 
dŚĞƌĞĂƌĞƚŚƌĞĞĐůĂƐƐ/W/ ?<ĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚƐ ?Ɖ ? ? ?ɲ ?Ɖ ? ? ?ɴĂŶĚƉ ? ? ?ɷ ?ǁŚŝĐŚĐĂŶďŝŶĚŽŶĞŽĨ ?435 
SH2-ĚŽŵĂŝŶĐŽŶƚĂŝŶŝŶŐƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚƐ ?Ɖ ? ?ɲ ?Ɖ ? ?ɲ ?Ɖ ? ?ɲ ?Ɖ ? ?ɴĂŶĚƉ ? ?ɶ ? ?dŚĞƌĞŝƐůŝƚƚůĞ436 
evidence for any preferential binding by either of the catalytic subunits for either of the regulatory 437 
ƐƵďƵŶŝƚƐ ?dŚĞĐůĂƐƐ/W/ ?<ĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚƉ ? ? ?ɶĐĂŶďŝŶĚƚŽĞŝƚŚĞƌƉ ? ?ŽƌƉ ? ? ? ?dŚĞůĂƚƚĞƌůĂĐŬ^, ?438 
domains and are instead recruited to G-protein coupled receptors. To date, PIDs have been 439 
described with LOF or GOF mutations in PIK3R1 or PIK3CD ?ĂĨĨĞĐƚŝŶŐƉ ? ?ɲĂŶĚƉ ? ? ?ɷ ?ƌĞƐƉĞĐƚŝǀĞůǇ ? 440 
Several amino acid substitution mutations have been described in PIK3CD. In PIK3R1, all mutations 441 
described that cause APDS2 results in alternative splicing such that the mature mRNA lacks sequence 442 
from exon 11. Although this is strictly speaking a loss of inhibitory function mutation, we describe it 443 
ĂƐĂ'K&ŵƵƚĂƚŝŽŶŝŶƚŚŝƐƌĞǀŝĞǁĂƐŝƚůĞĂĚƐƚŽŐĂŝŶŽĨW/ ?<ɷĂĐƚŝǀŝƚǇĂŶĚŝƐĚŝƐƚŝŶĐƚĨƌŽŵƚŚĞ complete 444 
>K&ŽĨW/< ?Z ?ǁŚŝĐŚůĞĂĚƐƚŽůŽƐƐŽĨW/ ?<ɷ ?445 
 446 
  447 
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Figure 1. BCR signaling 448 
/ŶĐĞůůƐ ?W/ ?<ɷŝƐĂĐƚŝǀĂƚĞĚƵƉŽŶĐƌŽƐƐ-linking of the BCR, after stimulation with IL-4 or by the 449 
chemokine CXCL13. The BCR coopts the co-receptor CD19 or the adapter protein BCAP, both of 450 
ǁŚŝĐŚŚĂǀĞzyyDŵŽƚŝĨƐƚŽǁŚŝĐŚƚŚĞƉ ? ?ɲ^, ?ĚŽŵĂŝŶƐĐĂŶďŝŶĚ ?dŚĞ/>-4R coopts IRS1, which also 451 
has YXXM motifs. The mechanism whereby CXCR5 is ĐŽƵƉůĞĚƚŽW/ ?<ɷƌĞŵĂŝŶƐƚŽďĞĚĞĨŝŶĞĚ ?ĐĞůůƐ452 
ĂƌĞƵŶƵƐƵĂůŝŶƚŚĂƚŵŽƐƚĐĞůůƐƵƐĞW/ ?<ɶŽƌW/ ?<ɴƚŽƚƌĂŶƐŵŝƚƐŝŐŶĂůƐĨƌŽŵ'WZƐ ?<ĞǇƚĂƌŐĞƚƐĨŽƌW/ ?<453 
signalling are FOXO1 and mTOR. FOXO1 is a transcription factor that activates the genes for RAG 454 
proteins involved in V(D)J recombination, IKAROS which is required for early B cell development, 455 
CD62L which is required for homing to lymph nodes and, AICDA which encoded AID. AID is required 456 
for CSR and SHM. The amino acid sensor mTOR contributes to the growth and proliferation of B cells. 457 
All proteins labelled in blue have been affected by LOF mutatŝŽŶƐĐĂƵƐŝŶŐW/ ?KĨƚŚĞƐĞ ?ŽŶůǇƉ ? ?ɲ458 
ĂŶĚƉ ? ? ?ɷŚĂǀĞĂůƐŽďĞĞŶĂĨĨĞĐƚĞĚďǇ'K&ŵƵƚĂƚŝŽŶƐĐĂƵƐŝŶŐW/ ? 459 
Figure 2. TCR signaling 460 
In T cells, the TCR, the costimulatory receptor ICOS and the IL- ?ZĐĂŶĂĐƚŝǀĂƚĞW/ ?<ɷ ?ǁŚĞƌĞĂƐW/ ?<ɶ461 
is activated by CXCR4 and other chemokine receptors. ICOS contains a YXXM motif in the 462 
cytoplasmic domain which is essential for ICOS-costimulation. How the TCR and IL- ?ZĂĐƚŝǀĂƚĞW/ ?<ɷ463 
ƌĞŵĂŝŶƐŝŶĐŽŵƉůĞƚĞůǇƵŶĚĞƌƐƚŽŽĚ ?sŝĂƚŚĞŝŶĂĐƚŝǀĂƚŝŽŶŽĨ&KyK ? ?W/ ?<ɷĐŽŶƚƌŝďƵƚĞƐƚŽƚŚĞ464 
downregulation of the expression of IL7Ra and CD62L, preparing the T cell to exit the lymph nodes 465 
and circulate through the vascular systems and organs. 466 
&ŝŐƵƌĞ ? ?W^ŵƵƚĂƚŝŽŶƐůŽǁĞƌƚŚƌĞƐŚŽůĚŽĨĂĐƚŝǀĂƚŝŽŶĨŽƌW/ ?<ɷ 467 
Class IA PI3Ks are activated by recruitment to tyrosine kinase-associated receptors at the plasma 468 
membrane. The Ɖ ? ?ɲ regulatory subunit (p50 fragment containing the nSH2-iSH2-cSH2) shown here 469 
in gold) stabilizes the Ɖ ? ? ?ɷcatalytic subunit (blue) through constitutive binding of the Ɖ ? ?ɲ inter-470 
SH2 domain (coiled portion) to the Ɖ ? ? ?ɷadaptor-binding domain (ABD). Binding of the Ɖ ? ?ɲ SH2 471 
domains to tyrosine-ƉŚŽƐƉŚŽƌǇůĂƚĞĚƌĞƐŝĚƵĞƐƌĞůĞĂƐĞƐŝŶŚŝďŝƚŽƌǇĐŽŶƚĂĐƚƐďĞƚǁĞĞŶƚŚĞƉ ? ?ɲ472 
SH2/inter-SH2 domains ĂŶĚƚŚĞƉ ? ? ?ɷC2, helical, and kinase domains. Both the Ɖ ? ?ɲ N-and C-SH2 473 
ĚŽŵĂŝŶƐŝŵƉŽƐĞŶĞŐĂƚŝǀĞƌĞŐƵůĂƚŝŽŶŽĨƉ ? ? ?ɷ ?ǁŚĞƌĞĂƐƉ ? ? ɲŝƐŽŶůǇĂĨĨĞĐƚĞĚďǇƚŚĞE-SH2 domain 474 
(not shown). It is possible that the ȴEx11 mutation (purple) truncating ƚŚĞƉ ? ?ɲŝnter-SH2 domain 475 
ĂĨĨĞĐƚƐƉ ? ? ?ɷŵŽƌĞƚŚĂŶŝƚĂĨĨĞĐƚƐƉ ? ? ?ɲ ?ŚĞŶce the lack of more pleiotropic effects on growth and 476 
metabolism. Ras-'dWĨƵƌƚŚĞƌƚĞƚŚĞƌƐƉ ? ? ?ɷƚŽthe membrane by binding to the Ras-binding domain 477 
(RBD) ŽĨƉ ? ? ?ɷ ?GOF mutations in PIK3R1 and PIK3CD increase kinase activity by interfering with 478 
inhibitory interactions between the p85ɲ ƌĞŐƵůĂƚŽƌǇĂŶĚƉ ? ? ?ɷĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚ (ȴEx11, N334K, 479 
C416R, E525K), or by increasing the affinity of Ɖ ? ? ?ɷĨŽƌƚŚĞƉůĂƐŵĂŵĞŵďƌĂŶĞ (E1021K). The E1021 480 
<ŵƵƚĂƚŝŽŶƐŵĂǇĂůƐŽŝŶƚĞƌĨĞƌĞǁŝƚŚŝŶŚŝďŝƚŽƌĐŽŶƚĂĐƚƐĨƌŽŵƚŚĞƉ ? ?ɲ-terminal SH2 domain (not 481 
shown)
1
.  See ref (
17
) and references therein for further details of the structures and mechanisms of 482 
ƌĞŐƵůĂƚŝŽŶŽĨW/ ?<ɷ ?483 
&ŝŐƵƌĞ ? ?ǇŶĂŵŝĐƌĞŐƵůĂƚŝŽŶŽĨW/ ?<ɷƐŝŐŶĂůŝŶŐŝŶƚŚĞŝŵŵƵŶĞƐǇƐƚĞŵ 484 
W/ ?<ɷĂĐƚŝǀŝƚǇŶĞĞĚƐƚŽďĞĚǇŶĂŵŝĐĂůůǇƌĞŐƵůĂƚĞĚĨŽƌŶŽƌŵĂůŝŵŵƵŶĞĐĞůůĨƵŶĐƚŝŽŶĂƐƐŽŵĞĐĞůůƚǇƉĞƐ485 
and processes require high W/ ?<ɷĂĐƚŝǀŝƚǇ ?ǁŚŝůĞŽƚŚĞƌĚĞƉĞŶĚŽŶůŽǁW/ ?<ɷĂĐƚŝǀŝƚǇ ?ĞŐŝĨƚŚĞǇ486 
require Foxo1-dependent transcription of genes. Problems arise if cells cannot increase or suppress 487 
W/ ?<ɷĂĐƚŝǀŝƚǇ ?ďƵƚƌĂƚŚĞƌ ?ŚĂǀĞĐŚƌŽŶŝĐĂůůǇůŽǁŽr high activity as a consequences of mutations. In 488 
both cases, immunosuppression occurs. Illustrated are some key cell types and processes affected by 489 
ŚŝŐŚŽƌůŽǁW/ ?<ɷĂĐƚŝǀŝƚǇ ?ĂŶĚƚŚĞĐŽŶƐĞƋƵĞŶĐĞƐŽĨďĞŝŶŐůŽĐŬĞĚŝŶŽŶĞƐƚĂƚĞŽƌƚŚĞŽƚŚĞƌ ? 490 
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Box 1. Clinical features of APDS 491 
Patients with APDS display features of both immune deficiency and of immune dysregulation 492 
x Recurrent lung, ear and sinus infections (with encapsulated bacteria such as Haemophilus 493 
influenzae and Streptococcus pneumoniae, which require opsonisation for effective killing) 494 
are near-universal, and associated with a high incidence of organ damage including hearing 495 
impairment and bronchiectasis (permanent airway scaring)
1-4
 496 
x Severe, recurrent or persistent infections with herpes family viruses are common, in 497 
particular chronic EBV or CMV viremia, and HSV and VZV infections
1, 3-7
. Frequent isolates of 498 
some respiratory viruses such as adeno- and echovirus have also been described
 1
 499 
x Opportunistic infections are rare although a few patients have experienced recurrent viral 500 
warts or Molluscum contagiosum infections
49
  501 
x An increased incidence of abscess formation, lymphadenitis and cellulitis with gram-positive 502 
bacteria (mainly Staphylococcus aureus), and defective killing of mycobacteria by 503 
macrophages from an APDS patient suggest a mild deficit in innate immunity
1, 64
. 504 
x Benign lymphoproliferation (lymphadenopathy, hepatosplenomegaly and focal nodular 505 
lymphoid hyperplasia) is a common feature of all studies of APDS to date.  506 
x Histopathologically, lymphoid tissue demonstrates atypical follicular hyperplasia with 507 
attenuation of mantle zones in APDS1, and small B cell follicles in APDS2. Germinal centres 508 
were disrupted in both APDS1 and APDS2 by infiltrating T-cells (often PD1-positive)
6, 7
. 509 
x There is a high frequency of lymphoma in APDS, encompassing a wide range of 510 
histopathological patterns
1, 2, 7, 65, 67
 511 
x Immune cytopenias (thrombocytopenia, haemolytic anaemia and neutropenia,  and  auto-512 
immune-like solid organ conditions (e.g. juvenile arthritis, glomerulonephritis, thyroiditis and 513 
sclerosing cholangitis) have also been reported
7, 66
, with a frequency of 34% in a cohort of 53 514 
patients with APDS1 
7
 and 17% in a cohort of 36 patients with APDS2 
6
. 515 
x Mild developmental delay has been observed in both APDS1 and APDS2 cohorts, with a 516 
higher incidence in APDS2 (31% versus 19%) 
6, 7
 517 
x Growth retardation is common in APDS2 6, 71, 72 but does not seem to be a feature of APDS1, 518 
and may relate to the association of heterozygous PIK3R1 mutations with SHORT syndrome 519 
(Short stature, hyperextensibility of joints, hernia, ocular depression, Rieger anomaly, and 520 
teething delay)
85-88
. 521 
 522 
Box 2: Lessons learned from APDS 523 
ůƚŚŽƵŐŚ ƚŚĞ ŶŽƌŵĂů ƉŚǇƐŝŽůŽŐŝĐĂů ƌŽůĞ ŽĨ W/ ?<ɷ ŚĂƐ ďĞĞŶ ĞǆƚĞŶƐŝǀĞůǇ ƐƚƵĚŝĞĚ ŝŶ ŵŽƵƐĞ ŵŽĚĞůƐ ?524 
investigation of APDS patients has provided important new insights about the biology of this kinase 525 
in humans.  526 
x DƵƚĂƚŝŽŶƐĐĂƵƐŝŶŐ>K&Žƌ'K&ŽĨW/ ?<ɷůĞĂĚƚŽŝŵŵƵnodeficiency. This illustrates how this 527 
pathway needs to be dynamically regulated for normal immune cell function 528 
x dŚĞ ƉƌĞǀŝŽƵƐůǇ ƌĞƉŽƌƚĞĚ ƌŽůĞƐ ĨŽƌ W/ ?<ɷ ŝŶ  ĐĞůů ĨƵŶĐƚŝŽŶ ĂŶĚ ŚƵŵŽƌĂů ŝŵŵƵŶŝƚǇ ĚŝĚ ŶŽƚ529 
predict the preponderance of transitional B cells observed in APDS patients.  530 
x Defects in CSR not attributable to defective AID mRNA expression remain to be fully 531 
understood.  532 
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x Augmented PI3K results in loss of naïve cells and an in-vivo proliferative burst that causes 533 
lymphoproliferative disease and pushes the T cells toward cellular senescence (a phenotype 534 
that is poorly mimicked in mouse models due to long telomeres).  535 
x Moreover, patient T cells are highly susceptible to TCR restimulation-induced cell death, 536 
indicating a previously unappreciated pro-apoptotic ƐŝŐŶĂůůŝŶŐƌŽůĞĨŽƌW/ ?<ɷ ? 537 
x The high proportion of patients with severe respiratory infections and bronchiectasis 538 
ƐƵŐŐĞƐƚƐ Ă ƌŽůĞ ĨŽƌW/ ?<ɷ ŝŶ ƉƌŽŵŽƚŝŶŐ ŝŶĨůĂŵŵĂƚŝŽŶ ŽĨ ƚŚĞ ůƵŶŐƐ ďǇŵĞĐŚĂŶŝƐŵƐ ƚŚĂƚ ĂƌĞ539 
incompletely understood, but which may indicate a key ƌŽůĞĨŽƌW/ ?<ɷŝŶĂŝƌǁĂǇ-associated 540 
innate immune responses, in addition to its role in humoral immunity. 541 
x Previously, LOF point mutations in PIK3R1 were shown to cause SHORT syndrome 85-88. It is 542 
unclear why the ȴEx11 mutations that cause APDS2 manifest primarily as PID; however, it is 543 
of interest to note at least one case where this mutation was linked with SHORT syndrome 544 
71 ?dŚŝƐŝŶĚŝĐĂƚĞƐƚŚĂƚW/< ?Z ?ȴEx11 may have distinct effects on different p110 isoforms in 545 
different tissues.   546 
 547 
  548 
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Glossary terms 801 
 802 
APDS/PASLI 803 
APDS stands for Activated PI3K Delta Syndrome whereas PASLI stands for P110ɷ-Activating mutation 804 
causing Senescent T cells, Lymphadenopathy, and Immunodeficiency. Both refer to mutation in the 805 
W/< ?ŐĞŶĞƚŚĂƚůĞĂĚƚŽŚǇƉĞƌĂĐƚŝǀĂƚŝŽŶŽĨƚŚĞƉ ? ? ?ɷƐƵďƵŶŝƚŽĨW/ ?<ɷ ?APDS-2/PASI-R1 refer to 806 
ƐƉůŝĐĞŵƵƚĂƚŝŽŶƐŝŶW/< ?Z ?ƚŚĂƚůĞĂĚƚŽĞǆŽŶƐŬŝƉƉŝŶŐƌĞƐƵůƚŝŶŐŝŶƚƌƵŶĐĂƚĞĚƉ ? ?ɲƉƌŽƚĞŝŶǁŝƚŚ807 
reduced inhibition of Ɖ ? ? ?ɷ ? 808 
 809 
Activation-Induced cytidine Deaminase (AID) 810 
An enzyme that is required for two crucial events in the germinal centre: somatic hypermutation and 811 
class-switch recombination. 812 
 813 
Germinal centre reaction 814 
Germinal centres are specialise structures within spleens or lymph nodes where B cells present 815 
antigen to T cells and in return, are selected to undergo CSR and SHM. 816 
 817 
Immunoglobulin class-switch recombination (CSR) 818 
The process by which a heavy-chain variable region gene segment attached to one heavy-chain 819 
constant region gene segment in the expressed heavy-chain gene is recombined with a downstream 820 
constant region gene segment to express a new antibody class. 821 
 822 
T cell-independent antibody response (TI) 823 
An antibody response to polymeric antigens, such as polysaccharides and lipids, that does not 824 
require T cell help. 825 
 826 
Primary Immunodeficiency (PID) 827 
Inherited disorders of the immune system that lead to recurrent infections and/or immune 828 
dysregulation. Currently there are around 84,000 PID patients diagnosed worldwide. 829 
 830 
Somatic hypermutation (SHM) 831 
A unique mutation mechanism that is targeted to the variable regions of rearranged immunoglobulin 832 
gene segments. Combined with selection for B cells that produce high-affinity antibody, SHM leads 833 
to affinity maturation of B cells in germinal centres. 834 
 835 
T follicular helper cells (Tfh) 836 
CD4
+
 T helper cells that are essential for the induction of class switching in the germinal centres of 837 
secondary follicles during antibody responses to T cell-dependent antigens. 838 
TH0 cells 839 
 840 
Transitional B cells 841 
Immature B cells that have left the bone marrow for the spleen and are precursors for follicular B 842 
cells, Marginal Zone B cells and B1 cells. 843 
 844 
Senescence 845 
A state in which a cell fails to progress through the cell cycle due to activation of the DNA damage 846 
response, which can occur upon extreme shortening of telomeres. 847 
